Biotechnology Innovation Organization reposted this
As #BIO2024 has come to an end, our CEO, Monika Paule, shared how Caszyme's CRISPR solutions are advancing the field of biotechnology with the I am Bio podcast 🧬🚀 #CRISPR #geneediting
Chief Executive Officer at Caszyme, Vice President at LithuaniaBIO, Professional Board Member, Innovations Expert & Entrepreneur
It was an inspiring week at #BIO2024 in San Diego! Enjoyed sharing my take with BIO Podcast series. #CRISPR #geneediting #Caszyme
Looking to cut costs and boost growth? BIO Business Solutions® offers deep discounts on essential products and services. Discover how you can save as a BIO member : https://lnkd.in/gnspKMth
📣 Have your voice heard! Become a BIO member and join our committees to participate in the conversations that shape industry standards and policies. https://lnkd.in/eyNtMA5
BIO will continue to be a voice for science and empower biotech innovators to improve lives. The Agriculture and Environment Section champions agriculture and environmental biotech innovations that will allow the bioeconomy to thrive. #ABCsofClimateTech https://lnkd.in/eJpDaFmG
Optimize your lab operations with our cost savings programs! BIO Business Solutions® negotiates significant, volume-based discounts and favorable terms on your behalf. Learn more: https://lnkd.in/deCBU79W
Early bird for #BIF24 ends August 25! Don't miss your opportunity to connect with executives, innovators, investors, and institutions dedicated to advancing patient care. Register now: https://lnkd.in/dFy3uU4W
Scientists use vectors to carry a DNA segment, and thus are a necessary component in genetic engineering and some animal vaccine development. We can create vaccines for well-known illnesses in animals like influenza, West Nile virus, and rabies. #ABCsofClimateTech
🎉Congratulations to BIO member Servier Pharmaceuticals on their recent FDA approval for Voranigo!
#BreakingNews We are thrilled to announce that today, the U.S. FDA has approved the first targeted therapy for Grade 2 IDH-mutant glioma. This is the first significant treatment breakthrough for this relentless condition in nearly 25 years. Thank you to the dedicated study participants, researchers, and clinical investigators who made this achievement possible. Learn more about this approval and Servier’s mission to bring transformative new therapies to patients: https://ow.ly/k68U50SRETr
